Traders Alert: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), MGIC Investment Corp. (NYSE:MTG)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

The company announced its last quarter financial performance results on 11/07/2016. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Medical sector that surged 0.42% in value when last trading session closed at $23.95. The company has a market capitalization of $4.66 Billion. The company’s stock has a Return on Assets (ROA) of -5.4 percent, a Return on Equity (ROE) of 37.1 percent and Return on Investment (ROI) of -62.9 percent. The company reached its 52-Week high of $23.95 on Feb 13, 2017 and 52-Week low of $4.67 on Feb 24, 2016.

Earnings per share (ttm) for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) according to Finviz Data is $-0.18.

This company was Downgrade by SunTrust on 11-Jan-17  to Hold.

The 8 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 24.00 and a low estimate of 14.00. The median estimate represents a +0.21% increase from the last price of 23.95.

Financial History:

Following Earnings result, share price were DOWN 15 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 58% percent of times. It has met expectations  0 times and missed earnings  5  times.

The consensus recommendation for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is 2.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.5. In comparison, the consensus recommendation 60 days ago was at 2.33, and 90 days ago was at 2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Ariad Pharmaceuticals Inc. to have earnings per share of $-0.18.

Revenue is expected to range from 42.5 Million to 47.57 Million with an average of 44.15 Million.

Company Profile:

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology.  The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology.  The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

MGIC Investment Corp. (NYSE:MTG):

MGIC Investment Corp. (NYSE:MTG) belongs to Finance sector closed its last session with a gain of 0.54 percent and closed its previous trading session at $11.26. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $0.86. The company has the Market capitalization of $3.81 Billion. The company’s stock has a Return on Assets (ROA) of 5.9 percent, a Return on Equity (ROE) of 13.7 percent and Return on Investment (ROI) of 11.2 percent. The company reached its 52-Week high of $11.3 on Feb 13, 2017 and 52-Week low of $5.36 on Jun 27, 2016.

The growth estimate for MGIC Investment Corp. (NYSE:MTG) for the current quarter is 41.2 percent. The projected growth estimate for the next quarter is -3.8 percent. The company’s stock has grown by 60.52 percent in the past 5 years. For the next 5 years, the company is expected to grow by 7.5 percent.

This company was Initiated by BofA/Merrill on 17-Oct-16 to Buy.

The 9 analysts offering 12-month price forecasts for MGIC Investment Corp have a median target of 12.00, with a high estimate of 13.00 and a low estimate of 10.50. The median estimate represents a +6.57% increase from the last price of 11.26.

Financial History:

Following Earnings result, share price were UP 17 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 83% percent of times. It has met expectations  0 times and missed earnings  2  times.

The consensus recommendation for MGIC Investment Corp. (NYSE:MTG) is 1.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.43. In comparison, the consensus recommendation 60 days ago was at 1.71, and 90 days ago was at 1.71 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects MGIC Investment Corp. to have earnings per share of $0.24.

Revenue is expected to range from 252.18 Million to 274.4 Million with an average of 266.72 Million.

Company Profile:

MGIC Investment Corporation is a holding company which, through its wholly owned subsidiary, Mortgage Guaranty Insurance Corporation, is the leading provider of private mortgage insurance coverage in the United States to the home mortgage lending industry. Private mortgage insurance covers residential first mortgage loans and expands home ownership opportunities by enabling people to purchase homes with less than 20% down payments. If the home owner defaults, private mortgage insurance reduces and, in some instances, eliminates the loss to the insured institution.